CVE-2014-1695

Public Exploit

Description

Cross-site scripting (XSS) vulnerability in Open Ticket Request System (OTRS) 3.1.x before 3.1.20, 3.2.x before 3.2.15, and 3.3.x before 3.3.5 allows remote attackers to inject arbitrary web script or HTML via a crafted HTML email.

Category

4.3
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 3.26% Top 15%
Vendor Advisory opensuse.org Vendor Advisory secunia.com Vendor Advisory otrs.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://www.exploit-db.com/exploits/36842/ exploit
http://www.securityfocus.com/bid/65844 vdb entry
http://secunia.com/advisories/57018 third party advisory vendor advisory
https://www.otrs.com/security-advisory-2014-03-xss-issue vendor advisory
http://packetstormsecurity.com/files/131654/OTRS-3.x-Cross-Site-Scripting.html exploit
http://lists.opensuse.org/opensuse-updates/2014-03/msg00030.html vendor advisory
http://adamziaja.com/poc/201401-xss-otrs.html
http://www.osvdb.org/103781 vdb entry

Frequently Asked Questions

What is the severity of CVE-2014-1695?
CVE-2014-1695 has been scored as a medium severity vulnerability.
How to fix CVE-2014-1695?
To fix CVE-2014-1695, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2014-1695 being actively exploited in the wild?
It is possible that CVE-2014-1695 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~3% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.